Top 50 Ai For Computational Biology in Asia

Scala Biodesign utilizes a one-shot computational platform that combines evolutionary analysis and AI to enhance the stability, yield, and specificity of proteins for therapeutic and industrial applications. This technology addresses the limitations of natural proteins, which often lack the required resilience and efficiency for modern medical and manufacturing needs.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

Utilizes generative AI to design de novo genes and proteins that integrate multiple biological functions into compact therapeutic molecules. This approach addresses unmet medical needs by enabling the development of highly effective treatments with improved efficiency and specificity.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

TandemAI provides a physics-based and AI-driven platform that integrates computational analyses with wet lab experimentation to enhance drug discovery workflows. By offering a collaborative workspace and advanced algorithms, TandemAI enables research teams to accelerate the development of new therapeutics more efficiently than traditional methods.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

Neurolov offers a cloud‑native platform that runs curated machine‑learning models on genomics, transcriptomics, proteomics and phenotypic data to produce predictive biomarkers, pathway activity scores, and compound efficacy forecasts. The service automates data ingestion, preprocessing, feature engineering and model inference, delivering results through interactive dashboards and API endpoints for integration with LIMS and downstream analysis. By providing a managed, scalable compute environment with versioned model registries and GxP/HIPAA compliance, it shortens the turnaround time for drug discovery teams.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

The startup develops a bioinformatics platform that employs artificial intelligence to analyze fetal cell-free DNA extracted from maternal blood samples during the first trimester. This technology enables early detection of genetic disorders, including point mutations and chromosomal anomalies, in a non-invasive and cost-effective manner.

Engine Biosciences utilizes machine learning and high-throughput biology to identify genetic interactions within complex disease networks, enabling the development of targeted therapeutics and biomarkers for specific patient populations. This approach significantly accelerates the research and development process for new medical therapies, reducing costs and improving clinical outcomes for a range of solid tumors.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

This biotechnology company utilizes artificial intelligence to cultivate and evolve proteins essential for bio-products, enhancing the efficiency of medical research. By providing reliable and rapid access to these proteins, the company addresses the need for improved medical services in the healthcare sector.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

Enzymit develops a cell-free bioproduction platform utilizing computational protein design and high-throughput testing to create novel enzymes for various industries, including biochemicals and health. This technology addresses the inefficiencies and high costs associated with traditional enzymatic manufacturing processes, enabling faster and more sustainable production.

OncoHost utilizes its PROphet® platform, which employs bioinformatic proteomic pattern recognition and AI, to generate a personalized PROphet® score that predicts the efficacy of PD-1/PD-L1 inhibitors in cancer therapy. This blood-based test provides actionable insights for clinicians, enabling tailored treatment strategies that aim to improve patient outcomes before therapy initiation.

Adagene operates an AI‑driven antibody discovery platform that models the full conformational landscape of target proteins to identify high‑affinity binders. The system generates three proprietary formats—NEObody for targeting previously inaccessible epitopes, SAFEbody for tumor‑localized activation via precision masking, and POWERbody that combines masking with bispecific, ADC, or T‑cell engager configurations. The company offers these candidates as licensed assets or co‑development projects to biopharma partners seeking safer, multi‑modal oncology therapeutics.

Unnatural Products utilizes an AI-enhanced discovery platform to engineer synthetic macrocycles that mimic natural macrocycles, enabling targeted therapies for complex drug targets that are typically undruggable by small molecules or biologics. This approach addresses the limitations of existing drug modalities by providing a new class of therapeutics with improved cell permeability and oral bioavailability.

Minutia.AI develops probabilistic AI models to simulate the complex interactions within the human gut microbiome, enabling personalized predictions of individual responses to dietary interventions. Their technology addresses the limitations of traditional biomarker approaches by providing granular insights into microbial dynamics and facilitating tailored dietary recommendations for improved health outcomes.

Biomica develops microbiome-based therapeutics using a proprietary computational platform that integrates metagenomics sequencing and AI to identify optimal microbial candidates for treating cancer, immune-mediated, and infectious diseases. The company addresses the challenge of unmet medical needs by maximizing therapeutic efficacy while minimizing adverse effects through carefully curated microbial consortia.

Provides an AI-powered platform, MoleculeGEN, for de novo drug design and antibody generation, leveraging deep learning and biophysics to create novel small molecules and antibodies tailored to specific disease targets. This approach addresses the challenges of traditional drug discovery by automating hit generation, lead optimization, and toxicity prediction, enabling faster development of treatments for diseases with high unmet medical needs.

HITS develops AI-driven digital solutions for drug discovery, utilizing advanced molecular design and predictive modeling to enhance the efficiency of early-stage drug development. The platform addresses the challenges of traditional drug discovery by providing accurate predictions for drug-protein interactions and optimizing molecular properties, significantly reducing time and costs associated with the development process.

AION Labs is a venture studio that utilizes AI and computational technologies to enhance drug discovery and development processes by integrating extensive pharma data and real-time validation against industry standards. The company addresses inefficiencies in drug development by providing funding, expert collaboration, and structured support for scientists and tech founders tackling specific biopharma challenges.

CYBO develops an AI-driven platform for cell analysis that utilizes high-speed imaging and deep learning to classify and sort cells efficiently. This technology enhances applications in medical diagnostics and pharmaceutical production by providing rapid and accurate cell characterization, addressing the challenges of traditional cell analysis methods.

The startup develops an AI bioinformatics platform that utilizes big data analytics and predictive modeling to streamline the identification and validation of drug targets. By simplifying complex biomedical data networks, the platform enables biochemists to gain actionable insights for target identification and drug repurposing.

Sravathi AI Technology Pvt Ltd utilizes proprietary AI algorithms and molecular modeling to design and develop drug molecules, polymers, and catalysts, enhancing the efficiency of chemical synthesis and in-vitro screening. The company addresses the challenge of predicting chemical reactions and optimizing yields at atomic and electronic levels, facilitating faster drug discovery and development processes.

Massive Bio offers an AI‑powered platform that consolidates clinical trial data, drug pipelines, and genomic test results into a searchable hub. Its machine‑learning engine matches patients’ clinical profiles and biomarkers to generate real‑time eligibility scores and treatment recommendations, delivered via a secure physician dashboard and patient mobile app.

The startup has developed an AI-powered drug discovery platform that utilizes data-driven methodologies to enhance traditional drug design processes. By providing scientists in the pharmaceutical industry with user-friendly AI tools, the platform accelerates research timelines and facilitates the development of novel therapeutics, ultimately aiming to reduce the burden of diseases on patients.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

Genz develops AI algorithms for genomic data analysis to facilitate personalized treatment plans for women with breast cancer. By leveraging advanced data analytics, the company aims to enhance the precision of therapeutic interventions tailored to individual genetic profiles.

Molcure offers an AI-driven platform that combines a proprietary large‑language model trained on over one billion antibody and peptide sequences with integrated directed‑evolution and next‑generation sequencing workflows. The system generates de novo candidates and optimizes existing leads using deep‑learning and physics‑based simulations, delivering faster hit discovery, higher affinity predictions, and seamless integration via cloud analytics and API endpoints for pharma, biotech, and CRO R&D teams.

ProPhet utilizes AI and machine learning to predict protein dynamics and interactions with drug candidates, enabling the identification of small molecules for hard-to-target proteins. This approach addresses the challenge of discovering therapeutics for diseases previously deemed undruggable, enhancing the efficiency and accuracy of early-stage drug discovery.

Blue Raven AI develops foundational AI architectures that utilize formal logical reasoning and independent verification to enhance generative AI applications in fields like drug discovery and quantum computing. The technology enables credible output generation and continuous self-learning, facilitating novel knowledge discovery and autonomous problem-solving in complex scientific domains.

BiotaX utilizes AI-driven computational biology to construct natural microbial communities tailored for specific functions in health, food, agriculture, and climate applications. The platform addresses the challenge of harnessing the vast diversity of uncultured bacteria to develop effective microbial solutions for various industries.

The startup develops protein degradation drugs using an AI-enabled platform to identify and target disease-related proteins in cancer, neurodegenerative, and aging-related diseases. This approach provides researchers and pharmaceutical companies with a new class of therapeutics that can overcome drug resistance in life-threatening conditions.

PhenoTA utilizes advanced AI algorithms to analyze blood cell data from routine blood tests, providing detailed insights into individual health conditions. This technology enhances medical decision-making by delivering precise, actionable information that can lead to earlier diagnosis and improved patient outcomes.

Deep Longevity employs artificial intelligence to analyze biomarkers of aging, enabling accurate evaluations of biological age. This technology provides essential insights into the aging process, facilitating personalized health interventions and advancements in longevity research.

Kobiolabs develops microbiome-based therapeutics using its Smartiome® platform, which employs AI-driven multi-omics analysis to create targeted treatments for immune, metabolic, and neurological disorders. By harnessing the complex interactions of the human microbiome, the company aims to address various health conditions linked to microbial imbalances.

This startup provides a secure and customizable platform for genomic data analysis, optimizing compute architecture and standardizing bioinformatic algorithms for research, academia, and clinical stakeholders. By simplifying the complexities of genomic data processing, it enhances efficiency and accessibility for users in these fields.

Moldoc Biotech develops rapid in-vitro and in-silico solutions for high-throughput screening and regulatory registration of pharmaceutical, cosmetic, and food products. Their AI-based data integration tools enhance prediction models and streamline safety assessments, addressing the need for efficient product development and compliance in the biotechnology sector.

BathGenBio utilizes artificial intelligence to analyze extensive biobank data, including genomic and clinical information, to identify novel biomarkers and optimize drug discovery processes. The platform addresses the challenges of precision medicine by enhancing target discovery, drug response prediction, and drug repurposing for medical institutions and biotechnology companies.

The startup has developed an AI-assisted platform for identifying bacteria using gram stain images, specimens, and symptoms captured with optical microscopes. This technology enables clinicians to accurately determine the causative bacteria in infectious diseases, facilitating the selection of appropriate antibiotics to combat life-threatening infections.

The startup has developed an AI-based drug discovery engine that analyzes patient genetic data and disease mutations to identify the most effective medication for individual conditions. By comparing molecular and clinical profiles, the platform enhances treatment precision, ultimately improving patient outcomes and quality of life.

NUMENOS utilizes AI-driven Foundation Models to enhance drug development by integrating and analyzing real-world data and clinical trial data, enabling biomarker-driven target discovery and patient stratification. This approach significantly reduces trial sizes by 50-70% and increases trial significance by an average of 10 times, addressing the inefficiencies of traditional drug development methods.

Portrai utilizes AI-driven spatial transcriptomics to improve the accuracy and quality of biopsy samples, enabling detailed tissue characterization. This technology enhances diagnostic precision and supports the development of personalized treatment plans for patients.

Westlake Omics develops AI-powered proteomics technology that enhances the precision of tumor diagnostics through quantitative and spatial proteomics methods. By providing reliable diagnostic tools, the company aims to improve patient outcomes in clinical settings by enabling accurate tumor characterization.

AIGEN Sciences is an AI-driven platform that utilizes machine learning algorithms to accelerate drug discovery and development processes. The platform addresses the lengthy and costly nature of traditional drug research by providing data-driven insights that enhance target identification and compound optimization.

This biotech startup utilizes machine learning and artificial intelligence to enhance pathology image analysis for the early detection of nasopharyngeal cancer. By providing scalable technology, the company enables healthcare professionals to identify this cancer type more accurately and efficiently, improving patient outcomes.